Stroke drug may work hours later than thought
NCT ID NCT05752916
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a clot-busting drug called rhTNK-tPA can help people having a stroke when given 4.5 to 24 hours after symptoms begin. It included 570 adults with a stroke that did not involve a large blocked artery. The goal was to see if the drug leads to better recovery (less disability) at 90 days compared to standard antiplatelet therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA)
- What this could lead to
- If it works, this could extend the time window for clot-busting treatment in stroke patients, allowing more people to recover with less disability.
- What could go wrong
- This is a completed Phase 4 trial, but results are not yet published. The drug may not improve outcomes beyond standard care and carries a risk of bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?